<DOC>
	<DOCNO>NCT03006302</DOCNO>
	<brief_summary>This study enroll patient metastatic pancreatic cancer progress prior chemotherapy . Half participant receive epacadostat/pembrolizumab/cyclophosphamide ( CY ) /GVAX pancreas vaccine follow epacadostat/pembrolizumab/CRS-207 ( Arm A ) , half receive epacadostat/pembrolizumab/CRS-207 ( Arm B ) . The primary objective study determine recommend dose epacadostat combination ass survival subject treatment group .</brief_summary>
	<brief_title>Epacadostat , Pembrolizumab , CRS-207 , With Without CY/GVAX Pancreas Patients With Metastatic Pancreas Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Inclusion Criteria ( abbreviate ) : Documented adenocarcinoma pancreas Have disease progression prior chemotherapy metastatic pancreas cancer ( adjuvant neoadjuvant progression occur within 6 month complete regimen ) Presence least one measurable lesion Patient acceptance tumor biopsy accessible lesion 2 time point ( baseline study ) ECOG performance status 0 1 Life expectancy great 3 month Adequate organ marrow function define studyspecified laboratory test Exclusion Criteria ( abbreviate ) : Brain metastasis Clinical radiographic ascites ( trace amount may allow ) Rapidly progress disease Live vaccine within 30 day study treatment ( flu vaccine allow ) Surgery within 28 day study treatment ( exception minor procedure ) Use investigational agent device within 28 day study treatment . Chemotherapy , radiation , biological cancer therapy within 14 day study treatment . Prior treatment antiCTLA4 , antiPD1 , antiPDL1 , anti PDL2 , IDO inhibitor . Use growth factor within 14 day study treatment Use systemic steroid within 14 day study treatment immunosuppressive agent within 7 day study treatment . Use 2 g/day acetaminophen Use UGT1A9 inhibitor Use warfarin Use MAOIs drug significant MAOI activity within 21 day screen History Seratonin Syndome Known allergy penicillin sulfa Known suspect hypersensitivity monoclonal antibody study drug component Have artificial joint implant easily remove history infection associate implant Significant malignant pleural effusion New pulmonary embolism , extremity deep venous thromboembolism , portal vein thrombosis within 2 month study enrollment History autoimmune disease ( exception Graves Hashimoto 's disease , vitiligo , type I diabetes mellitus ) Gastrointestinal condition may affect drug absorption Significant heart disease heart disease require antibiotic prevention endocarditis History abnormal electrocardiogram ( ECG ) deem meaningful investigator History ( noninfectious ) pneumonitis require steroid , evidence interstitial lung disease active , noninfectious pneumonitis Pulse oximetry &lt; 92 % room air need supplemental home oxygen Infection HIV , hepatitis B hepatitis C Other condition , include alcohol drug dependence , intercurrent illness , lack sufficient peripheral venous access would affect patient 's ability comply study visit procedure Pregnant breastfeed woman Unwillingness inability follow study schedule reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>MK-3475</keyword>
	<keyword>PD-1</keyword>
	<keyword>IDO</keyword>
</DOC>